Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (482) Arrow Down
Filter Results: (482) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (482)
    • People  (1)
    • News  (27)
    • Research  (403)
    • Events  (2)
  • Faculty Publications  (365)

Show Results For

  • All HBS Web  (482)
    • People  (1)
    • News  (27)
    • Research  (403)
    • Events  (2)
  • Faculty Publications  (365)
← Page 19 of 482 Results →
  • September 1997 (Revised October 1997)
  • Case

Bayer AG (A)

By: John A. Quelch
Bayer's senior executives convene in Germany to consider submitting a $1 billion bid that would recover the Bayer brand name and trademark cross in North America, both of which were confiscated by the U.S. government after World War I. The group also sets out to assess... View Details
Keywords: Management Teams; Brands and Branding; War; Communication; Trademarks; Acquisition; Government and Politics; Biotechnology Industry; Biotechnology Industry; Germany; North America; United States
Citation
Find at Harvard
Related
Quelch, John A., and Robin Root. "Bayer AG (A)." Harvard Business School Case 598-031, September 1997. (Revised October 1997.)
  • 26 Jun 2000
  • Research & Ideas

Presentation Round-Up

self-proclaimed "infrastructure guy," panelist Steve Papa (HBS MBA '99) of Optigrab.com speculated that the future of e-business services will be marked by the same pull toward uniformity that took place in industry consolidations a... View Details
Keywords: by Martha Lagace & Kenneth Liss; Technology; Communications; Telecommunications
  • 01 Sep 2011
  • News

Green Day

Erica Diamond demo the "modlet" View a list of alumni working in green industry What does it mean to be green? It’s a trendy color these days, but over the years HBS alumni have demonstrated a long-standing commitment to environmental... View Details
Keywords: Julia Hanna;Sarah Auerbach; Agriculture; Manufacturing; Electric Power Generation, Transmission, Distribution; Utilities
  • 20 Mar 2012
  • First Look

First Look: March 20

Market Governments—Qualitative Evidence from a Biotechnology Multinational Authors:Prithwiraj Choudhury, James Geraghty, and Tarun Khanna Publication:Global Strategy Journal 2, no. 1 (February 2012) Abstract We build on the emerging... View Details
Keywords: Sean Silverthorne
  • April 1995 (Revised April 1999)
  • Teaching Note

Aberlyn Capital Management TN

By: Josh Lerner
Teaching Note for (9-294-083). View Details
Keywords: Biotechnology Industry; Biotechnology Industry
Citation
Purchase
Related
Lerner, Josh. "Aberlyn Capital Management TN." Harvard Business School Teaching Note 295-134, April 1995. (Revised April 1999.)
  • March 2025 (Revised April 2025)
  • Teaching Note

Moving Science: The Rowland Institute at Harvard

By: Maria Roche
Teaching Note for HBS Case No. 724-441. View Details
Keywords: Optics; Engineering; Higher Education; Strategy; Science; Buildings and Facilities; Research and Development; Real Estate Industry; Real Estate Industry
Citation
Purchase
Related
Roche, Maria. "Moving Science: The Rowland Institute at Harvard." Harvard Business School Teaching Note 725-441, March 2025. (Revised April 2025.)
  • March 2023
  • Case

Moderna

By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19.... View Details
Keywords: Health Pandemics; Research and Development; Digital Transformation; Health Testing and Trials; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Iansiti, Marco, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen, and Dave Habeeb. "Moderna." Harvard Business School Multimedia/Video Case 623-703, March 2023. (Click here to access this case.)
  • March 2022
  • Teaching Note

Digital Manufacturing at Amgen

By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This teaching note provides guidance for instructors teaching “Digital Manufacturing at Amgen,” case no. 621-008. View Details
Keywords: Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information Technology; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Technology Adoption; Biotechnology Industry; Biotechnology Industry; United States; California; Puerto Rico; Rhode Island
Citation
Purchase
Related
Greenstein, Shane, Kyle R. Myers, and Sarah Mehta. "Digital Manufacturing at Amgen." Harvard Business School Teaching Note 622-013, March 2022.
  • November 2020
  • Supplement

Valuing Celgene's CVR

By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details
Keywords: Mergers and Acquisitions; Value; Valuation; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Purchase
Related
Esty, Benjamin C., and Daniel Fisher. "Valuing Celgene's CVR." Harvard Business School Spreadsheet Supplement 221-705, November 2020.
  • October 2019 (Revised April 2020)
  • Background Note

Note on Funding Deep Tech Startups

By: Karim Lakhani, Peter Barrett and Noubar Afeyan
This Background Note provides essential information on funding deep technologies—those technologies that were inherently capital intensive, time consuming, risky, and potentially disruptive. Both dilutive and non-dilutive sources of investment are highlighted, along... View Details
Keywords: Entrepreneurship; Energy; Venture Capital; Corporate Finance; Initial Public Offering; Investment; Health Testing and Trials; Innovation and Invention; Technological Innovation; Intellectual Property; Product Design; Product Development; Information Technology; Research and Development; Risk and Uncertainty; Technology Industry; Technology Industry; United States; North America; Europe; Asia
Citation
Educators
Purchase
Related
Lakhani, Karim, Peter Barrett, and Noubar Afeyan. "Note on Funding Deep Tech Startups." Harvard Business School Background Note 620-029, October 2019. (Revised April 2020.)
  • September 2019
  • Case

Celgene: Business Development and Distributed Research

By: Peter Barrett and Kareem Reda
This case looks at the deal-making process between Celgene, a large publicly traded pharmaceutical company, and Agios, an early-stage biotech company. The framework of a potential deal is explored and the potential road-blocks to Agios’ profitability are discussed. ... View Details
Keywords: Negotiation Deal; Alliances; Collaborative Innovation and Invention; Research; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Barrett, Peter, and Kareem Reda. "Celgene: Business Development and Distributed Research." Harvard Business School Case 620-014, September 2019.
  • June 2014
  • Supplement

Merrimack Pharmaceuticals, Inc. (B)

By: Amy C. Edmondson, Bethany Gerstein and Melissa Valentine
In 2006, the leadership team at Merrimack Pharmaceuticals, Inc. had to decide whether to keep its R&D organization in functional departments or restructure it into interdisciplinary teams. This case follows the outcomes of this decision from 2006 to mid-2014, and... View Details
Keywords: Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Biotechnology Industry; Biotechnology Industry
Citation
Purchase
Related
Edmondson, Amy C., Bethany Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 614-083, June 2014.
  • April 2010
  • Teaching Note

The DiagnoFirst Opportunity (TN)

By: Robert C. Pozen
Teaching Note for [309112]. View Details
Keywords: Decisions; Investment; Risk and Uncertainty; Patents; Cash Flow; Venture Capital; Negotiation Deal; Health Care and Treatment; Opportunities; Law; Health Industry; Health Industry; United States; Europe
Citation
Purchase
Related
Pozen, Robert C. "The DiagnoFirst Opportunity (TN)." Harvard Business School Teaching Note 310-118, April 2010.
  • February 2010 (Revised April 2010)
  • Case

Organization and Strategy at Millennium (A)

By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark... View Details
Keywords: Transformation; Leading Change; Management Succession; Organizational Change and Adaptation; Competitive Strategy; Competitive Advantage; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (A)." Harvard Business School Case 710-415, February 2010. (Revised April 2010.)
  • January 2009
  • Teaching Note

Biocon: Launching a New Cancer Drug in India (TN)

By: Sunil Gupta and Das Narayandas
Teaching Note for [508026]. View Details
Keywords: Product Launch; Market Timing; Price; Distribution Channels; Marketing Strategy; Health Care and Treatment; Biotechnology Industry; Biotechnology Industry; India
Citation
Purchase
Related
Gupta, Sunil, and Das Narayandas. "Biocon: Launching a New Cancer Drug in India (TN)." Harvard Business School Teaching Note 509-039, January 2009.
  • August 2007 (Revised November 2008)
  • Case

Biocon: Launching a New Cancer Drug in India

By: Sunil Gupta and Das Narayandas
Kiran Majumdar-Shaw, the CEO of Biocon has to make product launch timing, pricing, channel, and communications mix decisions relating to the launch of BioMAb, a new cancer drug in India. View Details
Keywords: Price; Health Care and Treatment; Marketing Strategy; Product Launch; Planning; Biotechnology Industry; Biotechnology Industry; India
Citation
Educators
Purchase
Related
Gupta, Sunil, and Das Narayandas. "Biocon: Launching a New Cancer Drug in India." Harvard Business School Case 508-026, August 2007. (Revised November 2008.)
  • March 2006
  • Teaching Note

Stan Lapidus: Profile of a Medical Entrepreneur (TN)

By: Robert F. Higgins, Richard G. Hamermesh and Erin Seefeld
Teaching Note to (805-087). View Details
Keywords: Personal Development and Career; Entrepreneurship; Business Startups; Biotechnology Industry; Biotechnology Industry
Citation
Purchase
Related
Higgins, Robert F., Richard G. Hamermesh, and Erin Seefeld. "Stan Lapidus: Profile of a Medical Entrepreneur (TN)." Harvard Business School Teaching Note 806-149, March 2006.
  • April 2003 (Revised October 2004)
  • Case

Novartis: The Challenge of Success (B)

By: Sandra J. Sucher and Stacy McManus
When Dr. Daniel Vasella learned of the early Phase 1 trial results, he immediately decided what course of action Novartis would take. Students will be able to examine and assess the concrete steps, and the rationale behind them, that Novartis took in response to this... View Details
Keywords: Decision Making; Moral Sensibility; Innovation and Invention; Distribution; Product Development; Production; Problems and Challenges; Research and Development; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (B)." Harvard Business School Case 603-044, April 2003. (Revised October 2004.)
  • April 2003 (Revised October 2004)
  • Case

Novartis: The Challenge of Success (A)

By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details
Keywords: Decision Making; Health Testing and Trials; Innovation and Invention; Markets; Distribution; Product Development; Production; Problems and Challenges; Research; Research and Development; Complexity; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
  • 2007
  • Chapter

Fighting AIDS, Fighting Poverty: Customer Centric Marketing in the Generic Antiretroviral Business

By: Rohit Deshpandé and Zoe Chance
Keywords: Health Disorders; Poverty; Product Marketing; Customers; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Related
Deshpandé, Rohit, and Zoe Chance. "Fighting AIDS, Fighting Poverty: Customer Centric Marketing in the Generic Antiretroviral Business." In Business Solutions for the Global Poor: Creating Social and Economic Value, edited by V. Kasturi Rangan, John A. Quelch, Gustavo Herrero, and Brooke Barton. John Wiley & Sons, 2007.
  • ←
  • 19
  • 20
  • …
  • 24
  • 25
  • →
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.